share_log

Jefferies Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $15

Benzinga Real-time News ·  Dec 21, 2022 06:21

Jefferies analyst Kelly Shi initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment